ACROSTUDY: Status update on 469 patients

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 34-38

  Brue, Thierry ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Acromegaly; Growth hormone; Observational study; Pegvisomant; Pituitary surgery; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; OCTREOTIDE; PEGVISOMANT; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOCARCINOMA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY THROMBOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIARY TRACT SURGERY; CARCINOMATOSIS; CHOLELITHIASIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; EPILEPSY; FATIGUE; FEMALE; HEALTH SURVEY; HIP SURGERY; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; INCREASED APPETITE; INSOMNIA; ISCHEMIC HEART DISEASE; LIPOHYPERTROPHY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; METABOLIC SYNDROME X; OVARIECTOMY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TINGLING; STEREOTACTIC RADIOSURGERY; SWEATING; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TUMOR VOLUME; WEIGHT GAIN;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; YOUNG ADULT;

EID: 58549089292     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178035     Document Type: Conference Paper

References (6)

1. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G: Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006;154:467-477.
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001: 358: 1754-1759.
4. Trainer PJ: ACROSTUDY: an overview. Horm Res 2007;68(suppl 5):68-69.
5. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B: Experience from the German Pegvisomant Observational Study. Horm Res 2007;68(suppl 5):70-73.
6. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82.